CSPC Megalith Biopharmaceutical Co.,Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Explore linked clinical trials.37 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, otorhinolaryngologic disease, squamous cell carcinoma | Recruiting | Phase 3 | 2026-10-08 | NCT07768189 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | autosomal dominant Parkinson disease 4, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT07857135 | |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Platinum-resistant Fallopian Tube Cancer; Platinum-resistant Ovarian Cancer; Platinum-resistant Primary Peritoneal Cancer | Recruiting | Phase 3 | 2026-09-23 | NCT07708753 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07833735 | |
| A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-08-31 | NCT07714668 | |
| A Study of SYH2092 Injection in Healthy Participants | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 1 | 2026-08-20 | NCT07776041 | |
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-12 | NCT07761286 | |
| SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 3 | 2026-08-11 | NCT07758621 | |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-06 | NCT07750041 | |
| A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT07744763 | |
| A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions | High-grade Cervical Intraepithelial Lesions | Not yet recruiting | Phase 2 | 2026-07-14 | NCT07702656 | |
| A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors | Solid Tumor | Not yet recruiting | Not stated | 2026-07-06 | NCT07684261 | |
| Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-01 | NCT06927986 | |
| A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2026-06-26 | NCT07672223 | |
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer | Advanced Breast Cancer | Recruiting | Phase 2 | 2026-06-16 | NCT07597629 | |
| SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2026-06-11 | NCT07633873 | |
| SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-03 | NCT07622225 | |
| A Study of SYS6051 in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-05-15 | NCT07591285 | |
| A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC | non-small cell lung carcinoma | Not yet recruiting | Phase 3 | 2026-05-13 | NCT07376382 | |
| SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Not yet recruiting | Phase 3 | 2026-04-13 | NCT07526792 | |
| SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2026-03-04 | NCT07442565 | |
| SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma | Locally Advanced/Metastatic/Recurrent ESCC | Not yet recruiting | Phase 3 | 2026-02-18 | NCT07417735 | |
| Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-02-17 | NCT07415863 | |
| A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 3 | 2026-02-12 | NCT07406542 | |
| SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Not yet recruiting | Phase 2 | 2026-01-29 | NCT07374549 |